clinical trial · NCT04390399
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic CancerN-803Aldoxorubicin HClPD-L1 t-haNKNab-paclitaxelGemcitabineCyclophosphamide5-FluorouracilLeucovorin
brief summary
This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting (ie, first line maintenance, second line, or third line or greater) will be evaluated independently as a separate cohort.
started
Jul 21, 2020
primary completion
Oct 13, 2025
completion
May 31, 2026
last updated
Dec 15, 2025
official title
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol